3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Celyad Oncology's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was -300.39%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Celyad Oncology's 3-Year ROIIC % or its related term are showing as below:
CLYYF's 3-Year ROIIC % is ranked worse than 83.76% of 1324
companies
in the Biotechnology industry
Industry Median: -4.42
vs CLYYF: -300.39
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Celyad Oncology 3-Year ROIIC % Related Terms
Celyad Oncology 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Celyad Oncology's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CLYYF vs VRTX, REGN, ALNY: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Celyad Oncology's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Celyad Oncology 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Celyad Oncology's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Celyad Oncology's 3-Year ROIIC % falls into.
Celyad Oncology's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -1.574 (Dec. 2025) - -28.335 (Dec. 2022) )
/
( 2.469 (Dec. 2025) - 11.192 (Dec. 2022) )
=
26.761
/
-8.723
=
-306.79%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Celyad Oncology (CLYYF) has a 3-Year ROIIC % of -300.39 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Celyad Oncology and its competitors. According to the industry distribution chart, Celyad Oncology ranks #1109 out of 1324 companies in the Biotechnology industry, placing it in the top 83.8%.
Is Celyad Oncology's 3-Year ROIIC % too high?
Celyad Oncology's current 3-Year ROIIC % is -300.39. Based on the distribution chart, Celyad Oncology ranks #1109 out of 1324 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Celyad Oncology has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Celyad Oncology's 3-Year ROIIC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Celyad Oncology ranks #1109 out of 1324 companies for 3-Year ROIIC %. This places Celyad Oncology in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Celyad Oncology and its competitors. Celyad Oncology's current 3-Year ROIIC % is -300.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celyad Oncology stock overvalued right now?
Celyad Oncology (CLYYF) has a current 3-Year ROIIC % of -300.39. The stock's GF Value™ is $0.46, compared to a current price of $0.25 — trading 45.7% below its estimated fair value. The current 3-Year ROIIC % is -300.39. Celyad Oncology's overall GF Score™ is 13/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Celyad Oncology (CLYYF), the current 3-Year ROIIC % is -300.39 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Celyad Oncology (CLYYF) Overvalued in 2026?
Based on GuruFocus' analysis, Celyad Oncology stock appears to be undervalued.
The current stock price of $0.25 is trading 45.7% below its estimated GF Value™ of $0.46.
Key valuation signals for CLYYF:
3-Year ROIIC %: -300.39
GF Value™: $0.46 vs. price of $0.25 (45.7% below fair value)
No single metric tells the full story. See the CLYYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Celyad Oncology SA is a biopharmaceutical company focused on the discovery and development of technologies for chimeric antigen receptor T-cell (CAR T) therapies. The company focuses on solid tumors and hematological malignancies. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks, including CELYAD, C-CATH, C_CURE, CAR-T Cell, THINK, CYAD01 - Deplethink, CYAD02 - Cycle1, CwalityCAR, CYAD-101, and new engagers. The firm has Cardiology and Immuno-oncology operating segments. It generates the majority of its revenue from the Cardiology segment.
13GF Score
Get the complete analysis for CLYYF
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLYYF has been successfully added to your 
